Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/29880907http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/29880907http://www.w3.org/2000/01/rdf-schema#comment"

Background

In luminal androgen receptor (AR) tumours, FOXA1 may direct AR to sites occupied by ER in luminal tumours, thus stimulating proliferation.

Methods

AR and FOXA1 expression were evaluated by immunohistochemistry in 333 non-metastatic triple-negative breast cancers (TNBC). Positivity threshold was set at ≥ 1% staining. Lymphocytic infiltration, PD-L1expression, PIK3CA mutations, PTEN defects and BRCA1 promoter methylation were assessed.

Results

AR + /FOXA1 + tumours (42.4%) were more frequently: found in older patients, lobular, of lower nuclear grade, with more frequently PIK3CA mutations; exhibited less frequently BRCA1 promoter methylation, defects of PTEN and PD-L1 expression than others. Recurrence-free and overall survivals were significantly lower for AR + /FOXA1 + TNBC (median follow-up: 7.8 years).

Conclusions

AR + /FOXA1 + expression defines a luminal-like TNBC subgroup affected with a worse outcome compared to other TNBC and a higher risk of late recurrences. This subgroup appears enriched in PIK3CA mutations, suggesting a role for PI3K inhibitors in this subgroup."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.org/dc/terms/identifier"doi:10.1038/s41416-018-0142-6"xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Mollevi C."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Simony-Lafontaine J."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Gutowski M."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Crapez E."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Lamy P.J."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Jacot W."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Boissiere F."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Charon-Barra C."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Romieu G."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Guiu S."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Bourgier C."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/author"Chartron E."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/date"2018"xsd:gYear
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/name"Br J Cancer"xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/pages"76-79"xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/title"Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers."xsd:string
http://purl.uniprot.org/citations/29880907http://purl.uniprot.org/core/volume"119"xsd:string
http://purl.uniprot.org/citations/29880907http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/29880907
http://purl.uniprot.org/citations/29880907http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/29880907
http://purl.uniprot.org/uniprot/#_A0A087WUX9-mappedCitation-29880907http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29880907
http://purl.uniprot.org/uniprot/#_E2I6G1-mappedCitation-29880907http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29880907
http://purl.uniprot.org/uniprot/#_D2KF13-mappedCitation-29880907http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/29880907
▶